User login
Relapsing-remitting multiple sclerosis (RRMS) is a type of MS that is characterized by periods of disease flare-ups (relapses) and periods of recovery (remissions). RRMS often develops into secondary-progressive MS (SPMS), which is characterized by a patient’s disability steadily worsening. In this video, Daniel Kantor, MD, FAAN, FANA, and Benjamin Greenberg, MD, MHS, address important topics in both MS subtypes, including uncontrollable and modifiable risk factors, and how psychological health plays a role in the progression of MS in patients.
Disclosures
This video roundtable was produced by the Custom Programs division of Frontline Medical Communications.
The faculty received modest honoraria from the Custom Programs division of Frontline Medical Communications for their time participating in this roundtable. The faculty was solely responsible for the content presented.
Dr. Kantor reports relationships with Actelion, Avanir, Biogen, Celgene, Genentech, Mylan, Novartis, and Sanofi Genzyme.
Dr. Greenberg is a consultant for Novartis and EMD Serono, and has received grants from Genentech.
Relapsing-remitting multiple sclerosis (RRMS) is a type of MS that is characterized by periods of disease flare-ups (relapses) and periods of recovery (remissions). RRMS often develops into secondary-progressive MS (SPMS), which is characterized by a patient’s disability steadily worsening. In this video, Daniel Kantor, MD, FAAN, FANA, and Benjamin Greenberg, MD, MHS, address important topics in both MS subtypes, including uncontrollable and modifiable risk factors, and how psychological health plays a role in the progression of MS in patients.
Disclosures
This video roundtable was produced by the Custom Programs division of Frontline Medical Communications.
The faculty received modest honoraria from the Custom Programs division of Frontline Medical Communications for their time participating in this roundtable. The faculty was solely responsible for the content presented.
Dr. Kantor reports relationships with Actelion, Avanir, Biogen, Celgene, Genentech, Mylan, Novartis, and Sanofi Genzyme.
Dr. Greenberg is a consultant for Novartis and EMD Serono, and has received grants from Genentech.
Relapsing-remitting multiple sclerosis (RRMS) is a type of MS that is characterized by periods of disease flare-ups (relapses) and periods of recovery (remissions). RRMS often develops into secondary-progressive MS (SPMS), which is characterized by a patient’s disability steadily worsening. In this video, Daniel Kantor, MD, FAAN, FANA, and Benjamin Greenberg, MD, MHS, address important topics in both MS subtypes, including uncontrollable and modifiable risk factors, and how psychological health plays a role in the progression of MS in patients.
Disclosures
This video roundtable was produced by the Custom Programs division of Frontline Medical Communications.
The faculty received modest honoraria from the Custom Programs division of Frontline Medical Communications for their time participating in this roundtable. The faculty was solely responsible for the content presented.
Dr. Kantor reports relationships with Actelion, Avanir, Biogen, Celgene, Genentech, Mylan, Novartis, and Sanofi Genzyme.
Dr. Greenberg is a consultant for Novartis and EMD Serono, and has received grants from Genentech.
